Altimmune, Inc.
ALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | -0.93 | 0.23 | -1.77 |
| FCF Yield | -3.53% | -6.14% | -4.46% | -3.55% |
| EV / EBITDA | -13.23 | -6.78 | -16.33 | -20.68 |
| Quality | ||||
| ROIC | -10.13% | -12.62% | -14.25% | -19.22% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.63 | 0.89 | 0.86 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -58.46% | – | – | – |
| Free Cash Flow Growth | 38.55% | -14.96% | 7.80% | 32.65% |
| Safety | ||||
| Net Debt / EBITDA | 2.94 | 7.65 | 2.35 | 1.52 |
| Interest Coverage | 42.14 | -86.83 | -21,815.00 | -24,866.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 15,210.00 | 3,225.00 | 44,352.00 | 56,106.00 |